Abstract 3610: Estrogen receptor-mediated pharmacogenomic eQTLs as predictors of endocrine therapy response in breast cancer
Martin Meng, Huanyao Gao, August John, Arnab Ghosh et autres
Abstract Background: Approximately 70% of breast cancers are estrogen receptor-positive (ER+), and endocrine therapies, including selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs), are standard-of-care. However, interpatient variability in treatment response and relapse remains substantial, suggesting underlying germline pharmacogenomic factors that …
us (code pays fourni par la source)
0 citations
Cancer Research